325 related articles for article (PubMed ID: 27349974)
1. Part II: Checkpoint inhibitors in cancer therapy.
Daud AI
Immunotherapy; 2016 Jun; 8(7):761-2. PubMed ID: 27349974
[No Abstract] [Full Text] [Related]
2. Part I: Checkpoint inhibitors in cancer therapy.
Daud AI
Immunotherapy; 2016 Jun; 8(6):675-6. PubMed ID: 27197535
[No Abstract] [Full Text] [Related]
3. Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
Spain L; Larkin J
Immunotherapy; 2016 Jun; 8(6):677-9. PubMed ID: 27197536
[No Abstract] [Full Text] [Related]
4. Introduction: Cancer Immunology Special Issue-Immunotherapy.
Kawakami Y
Int Immunol; 2016 Jul; 28(7):317. PubMed ID: 27313100
[No Abstract] [Full Text] [Related]
5. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
Furness AJ; Quezada SA; Peggs KS
Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975
[No Abstract] [Full Text] [Related]
6. Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.
Gorris MAJ; Halilovic A; Rabold K; van Duffelen A; Wickramasinghe IN; Verweij D; Wortel IMN; Textor JC; de Vries IJM; Figdor CG
J Immunol; 2018 Jan; 200(1):347-354. PubMed ID: 29141863
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers associated with checkpoint inhibitors.
Manson G; Norwood J; Marabelle A; Kohrt H; Houot R
Ann Oncol; 2016 Jul; 27(7):1199-206. PubMed ID: 27122549
[TBL] [Abstract][Full Text] [Related]
8. Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.
Braschi-Amirfarzan M; Tirumani SH; Hodi FS; Nishino M
Korean J Radiol; 2017; 18(1):42-53. PubMed ID: 28096717
[TBL] [Abstract][Full Text] [Related]
9. Hiding in Plain Sight: Soluble Immunomodulatory Receptors.
Dahal LN; Schwarz H; Ward FJ
Trends Immunol; 2018 Oct; 39(10):771-774. PubMed ID: 30195467
[TBL] [Abstract][Full Text] [Related]
10. [Not Available].
Caux C; Bay JO
Bull Cancer; 2018 Dec; 105 Suppl 1():S1-S2. PubMed ID: 30595190
[TBL] [Abstract][Full Text] [Related]
11. Which checkpoint inhibitor? An embarrassment of riches for bladder cancer.
Gill DM; Sonpavde G; Pal SK; Agarwal N
Immunotherapy; 2017 May; 9(6):463-466. PubMed ID: 28472906
[No Abstract] [Full Text] [Related]
12. Atypical autoimmune adverse effects with checkpoint blockade therapies.
Friedman CF; Snyder A
Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802
[No Abstract] [Full Text] [Related]
13. Coinhibitory Pathways in Immunotherapy for Cancer.
Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
[TBL] [Abstract][Full Text] [Related]
14. What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events.
Miranda Poma J; Ostios Garcia L; Villamayor Sanchez J; D'errico G
Allergol Immunopathol (Madr); 2019; 47(3):303-308. PubMed ID: 29983240
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibition in ovarian cancer.
Hamanishi J; Mandai M; Konishi I
Int Immunol; 2016 Jul; 28(7):339-48. PubMed ID: 27055470
[TBL] [Abstract][Full Text] [Related]
16. Towards In Silico Prediction of the Immune-Checkpoint Blockade Response.
Chen K; Ye H; Lu XJ; Sun B; Liu Q
Trends Pharmacol Sci; 2017 Dec; 38(12):1041-1051. PubMed ID: 29089139
[TBL] [Abstract][Full Text] [Related]
17. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
18. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.
Hahn AW; Gill DM; Pal SK; Agarwal N
Immunotherapy; 2017 Jun; 9(8):681-692. PubMed ID: 28653573
[TBL] [Abstract][Full Text] [Related]
19. Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection.
Iivanainen S; Koivunen JP
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31952311
[TBL] [Abstract][Full Text] [Related]
20. Could PD-1/PDL1 immune checkpoints be linked to HLA signature?
Correale P; Saladino RE; Nardone V; Giannicola R; Agostino R; Pirtoli L; Caraglia M; Botta C; Tagliaferri P
Immunotherapy; 2019 Dec; 11(18):1523-1526. PubMed ID: 31865873
[No Abstract] [Full Text] [Related]
[Next] [New Search]
